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An exciting forum for cancer research
These are exciting times in cancer research; significant advances in cancer biology are now being
effectively translated into the clinic. The promising results of STI-571 (Gleevec) in chronic myeloid
leukemia and c-kit activated gastrointestinal stromal tumors and the encouraging results of EGF
receptor blockers in solid tumors offer a glimpse of a new era of mechanism-based approaches to
cancer therapeutics. In addition, technological advances such as gene expression profiling are allow-
ing the characterization of cancerous lesions at the molecular level and the identification of markers
of prognostic value.
In this context, we are proud to introduce Cancer Cell, a new forum for cutting-edge findings in
cancer research.The main goal of Cancer Cell is to publish highly significant work in all areas of can-
cer research. Cancer Cell will also feature review material, including Commentaries, Primers,
Previews, and Reviews, appealing to basic scientists and clinical oncologists alike. During its first
year, Cancer Cell will publish a Focus on a different tumor every month; this concise piece is meant
to provide, at a glance, the current status of each disease in terms of epidemiology, diagnosis, con-
ventional treatment and experimental therapeutics, relevant molecular targets involved in cancer
pathogenesis, prevention, and future challenges.
The inaugural issue of Cancer Cell reflects the scope of the journal, by including studies that pro-
vide a better understanding of the molecular mechanisms involved in cancer development (such as
the amplification of the MET oncogene in human gastric carcinoma, the identification of novel onco-
genic pathways in T cell acute lymphoblastic leukemias and the regulation of angiogenic signaling)
and reports on the development of sophisticated mouse models for ovarian carcinoma and acute
myeloid leukemia, which may contribute to the identification of diagnostic markers and the develop-
ment of preclinical testing of novel therapeutic approaches.Richard Klausner comments on the enor-
mous gap that exists between our appreciation of the molecular basis of tumorigenesis and our abil-
ity to translate these concepts into efficient prevention and genuine cures, and how this gap might be
overcome. Emerging technologies, such as the ones used in cancer genomics are described by
Barbara Weber in a Primer accessible to clinicians.The identification of molecular predictors of clini-
cal outcome, by gene expression profiling, and its implications for the treatment of breast cancer
patients are discussed by Robert Weinberg. As part of our efforts to bridge the gap between basic
scientists and clinical oncologists, Brian Druker summarizes the lessons drawn from the clinical suc-
cess of Gleevec in CML that may contribute to the clinical development of other molecularly targeted
therapies and Charles Sawyers discusses novel findings in the autoregulation of c-Abl and their
implications for cancer therapeutics.
I come to Cancer Cell after 15 years of experience in cancer research. I obtained my Ph.D. from
the University of Buenos Aires, Argentina, for my work on human breast cancer biology. After post-
doctoral training in France in AIDS research and in the development of mouse models for human
malignancies, I joined the faculty at Thomas Jefferson University in Philadelphia. My research there
focused on the role of the IGF-I receptor in proliferation, tumorigenesis, and apoptosis, leading to the
preclinical development of different approaches for IGF-I receptor targeting in tumors. From my col-
laborations with scientists at biotech companies and with clinicians, I came to recognize the need for
a dynamic forum that fosters the exchange of ideas across the entire cancer community. We now
have an opportunity to make Cancer Cell just such a journal, and this is an exciting challenge.
Assisting me in this new venture are Katharine Winkler, as an Associate Editor, and Judith Glaven as
a Consulting Editor. Kate has a background in cell cycle and checkpoint regulation. Judy’s research
focused on small GTPases and second messenger signaling, and she currently works as a Senior
Editor on Cell, Molecular Cell, and Developmental Cell.
For Cancer Cell to become an exciting forum for cancer research, we need you to contribute your
most innovative and significant work in the cancer field. In exchange, Cancer Cell will strive to pro-
vide a fast, fair, and constructive review process; the highest quality production values; and a dedi-
cated team of professional scientific editors, who are willing to discuss your research, respond to
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your presubmission inquiries, and ensure that all manuscripts are reviewed on the basis of scientific
merit and held to the highest standards of excellence and editorial consistency. Cancer Cell will also
provide press releases, enabling Cancer Cell articles to be covered by the popular press and other
high-profile research journals. As part of our launch, the first three issues of Cancer Cell will be avail-
able free online (http://www.cancercell.org) and they will be widely distributed at the forthcoming
AACR and ASCO conferences.
I would like to take this opportunity to acknowledge our Editorial Board for their commitment to
the journal and to express my most sincere gratitude to the entire staff of Cell Press for their valuable
advice and support in launching this journal. I also want to acknowledge the important role played by
Kevin Davies, who was Editor-in-Chief of Cell Press in 2001. Kevin appointed the editorial team and
was instrumental during the early stages of the launch.
I invite you to work together with us to develop this new forum for cancer research, and I look for-
ward to meeting you at conferences throughout the year.
Mariana Resnicoff
